Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/14/2017 07/17/2017 07/18/2017 07/19/2017 07/20/2017 Date
53.73(c) 53.73(c) 53.33(c) 54(c) 54.15 Last
746 068 684 842 616 378 872 546 71 087 Volume
-0.67% 0.00% -0.74% +1.26% +0.28% Change
More quotes
Financials ($)
Sales 2017 444 M
EBIT 2017 -242 M
Net income 2017 -240 M
Finance 2017 435 M
Yield 2017 -
Sales 2018 600 M
EBIT 2018 -152 M
Net income 2018 -158 M
Finance 2018 287 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 16,4x
EV / Sales2018 12,4x
Capitalization 7 707 M
More Financials
Company
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer.Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent,... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
07/13 SEATTLE GENETICS : Patent Application Titled "Optimal Dosing of a Cd19-Antibody ..
07/10 SEATTLE GENETICS : Daily Technical Summary Reports on Biotech Stocks -- PTC Ther..
07/06 SEATTLE GENETICS : to Host Conference Call and Webcast Discussion of Second Quar..
06/29 SEATTLE GENETICS : Submits Supplemental Biologics License Application to FDA for..
06/29 SEATTLE GENETICS : Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine S..
06/28 SEATTLE GENETICS : Takeda aim for first line Adcetris use
06/26 SEATTLE GENETICS, INC. (NASDAQ : SGEN) Files An 8-K Other Events
06/26 SEATTLE GENETICS INC /WA : Other Events, Financial Statements and Exhibits (form..
06/26 SEATTLE GENETICS : Takeda and Seattle Genetics Announce Positive Results from Ph..
06/26 SEATTLE GENETICS' : cancer drug outperforms traditional treatment
More news
Sector news : Biotechnology & Medical Research - NEC
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/17SunTrust Banks Lowers Seattle Genetics Q3 2017 Earnings Estimates to ($0.47) .. 
07/13Oppenheimer Asset Management Inc. Takes Position in Seattle Genetics, Inc. $S.. 
07/12AMICUS THERAPUTICS JUMPS 23%, SEVEN POTENTIAL BIOTECH BUYOUT TARGETS $FOLD $B..
1
07/12Insider Selling: Seattle Genetics, Inc. $SGEN CEO Sells $541,787.54 in Stock .. 
07/11AMICUS THERAPUTICS JUMPS 23%, SEVEN POTENTIAL BIOTECH BUYOUT TARGETS $FOLD $.. 
More tweets
Qtime:104
News from SeekingAlpha
07/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 4, 2017
06/29 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 29, 2017
06/26 Slim Margin Of Victory For Adcetris
06/26 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/26 PREMARKET LOSERS AS OF 9 : 05 am
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 58,2 $
Spread / Average Target 7,8%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Eric L. Dobmeier Chief Operating Officer
Todd E. Simpson Chief Financial Officer
Jonathan Drachman Chief Medical Officer, EVP-Research & Development
Vaughn B. Himes Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.1.06%7 707
INCYTE CORPORATION30.10%26 713
QUINTILES IMS HOLDINGS INC18.44%19 631
LONZA GROUP31.29%16 937
CELLTRION, INC.--.--%12 502
ALKERMES PLC4.37%8 827